Literature DB >> 24005771

Circulating T regulatory cells migration and phenotype in glioblastoma patients: an in vitro study.

Chiara Vasco1, Alessandra Canazza, Ambra Rizzo, Adele Mossa, Elena Corsini, Antonio Silvani, Laura Fariselli, Andrea Salmaggi, Emilio Ciusani.   

Abstract

Glioblastoma multiforme (GBM) is the most aggressive primary human brain tumor. The relatively high amount of T regulatory lymphocytes present in the tumor, contributes to the establishment of an immunosuppressive microenvironment. Samples of peripheral blood were collected from GBM patients and healthy controls and a purified population of Treg (CD4(+)/CD25(bright)) was isolated using flow cytometric cell sorting. Treg migrating capacities toward human glioma cell line conditioned medium were evaluated through an in vitro migration test. Our data show that supernatants collected from GBM cell lines were more attractant to Treg when compared to complete standard medium. The addition of an anti-CCL2 antibody to conditioned medium decreased conditioned medium-depending Treg migration, suggesting that CCL2 (also known as Monocyte Chemoattractant Protein, MCP-1) is implicated in the process. The number of circulating CD4(+)/μL or Treg/μL was similar in GBM patients and controls. Specific Treg markers (FOXP3; CD127; Helios; GITR; CTLA4; CD95; CCR2, CCR4; CCR7) were screened in peripheral blood and no differences could be detected between the two populations. These data confirm that the tumor microenvironment is attractive to Treg, which tend to migrate toward the tumor region changing the immunological response. Though we provide evidence that CCL2 is implicated in Treg migration, other factors are needed as well to provide such effect.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24005771     DOI: 10.1007/s11060-013-1236-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  36 in total

Review 1.  Resolving the identity myth: key markers of functional CD4+FoxP3+ regulatory T cells.

Authors:  Xin Chen; Joost J Oppenheim
Journal:  Int Immunopharmacol       Date:  2011-05-31       Impact factor: 4.932

2.  More on the immune privilege of glioblastoma.

Authors:  Michael Weller
Journal:  Neuro Oncol       Date:  2012-05       Impact factor: 12.300

Review 3.  Regulatory T cells in the central nervous system.

Authors:  Daniel E Lowther; David A Hafler
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

4.  An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme.

Authors:  Abdeljabar El Andaloussi; Maciej S Lesniak
Journal:  Neuro Oncol       Date:  2006-05-24       Impact factor: 12.300

5.  ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells.

Authors:  Julien Faget; Nathalie Bendriss-Vermare; Michael Gobert; Isabelle Durand; Daniel Olive; Cathy Biota; Thomas Bachelot; Isabelle Treilleux; Sophie Goddard-Leon; Emilie Lavergne; Sylvie Chabaud; Jean Yves Blay; Christophe Caux; Christine Ménétrier-Caux
Journal:  Cancer Res       Date:  2012-10-01       Impact factor: 12.701

Review 6.  Primary brain tumours in adults.

Authors:  Anthony Behin; Khe Hoang-Xuan; Antoine F Carpentier; Jean-Yves Delattre
Journal:  Lancet       Date:  2003-01-25       Impact factor: 79.321

7.  Systemic inflammatory response and downmodulation of peripheral CD25+Foxp3+ T-regulatory cells in patients undergoing radiofrequency thermal ablation for lung cancer.

Authors:  Anna Maria Fietta; Monica Morosini; Ileana Passadore; Alessandro Cascina; Paola Draghi; Roberto Dore; Sandro Rossi; Ernesto Pozzi; Federica Meloni
Journal:  Hum Immunol       Date:  2009-03-27       Impact factor: 2.850

8.  IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival.

Authors:  Derek A Wainwright; Irina V Balyasnikova; Alan L Chang; Atique U Ahmed; Kyung-Sub Moon; Brenda Auffinger; Alex L Tobias; Yu Han; Maciej S Lesniak
Journal:  Clin Cancer Res       Date:  2012-08-29       Impact factor: 12.531

Review 9.  Recent developments on immunotherapy for brain cancer.

Authors:  Derek A Wainwright; Pragati Nigam; Bart Thaci; Mahua Dey; Maciej S Lesniak
Journal:  Expert Opin Emerg Drugs       Date:  2012-04-25       Impact factor: 4.191

10.  Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers.

Authors:  Max Yan; Nicholas Jene; David Byrne; Ewan K A Millar; Sandra A O'Toole; Catriona M McNeil; Gaynor J Bates; Adrian L Harris; Alison H Banham; Robert L Sutherland; Stephen B Fox
Journal:  Breast Cancer Res       Date:  2011-04-26       Impact factor: 6.466

View more
  15 in total

1.  Boosting the peripheral immune response in the skeletal muscles improved motor function in ALS transgenic mice.

Authors:  Maria Chiara Trolese; Carlotta Scarpa; Valentina Melfi; Paola Fabbrizio; Francesca Sironi; Martina Rossi; Caterina Bendotti; Giovanni Nardo
Journal:  Mol Ther       Date:  2022-04-27       Impact factor: 12.910

2.  Characterising Distinct Migratory Profiles of Infiltrating T-Cell Subsets in Human Glioblastoma.

Authors:  Paris M Kollis; Lisa M Ebert; John Toubia; Cameron R Bastow; Rebecca J Ormsby; Santosh I Poonnoose; Sakthi Lenin; Melinda N Tea; Stuart M Pitson; Guillermo A Gomez; Michael P Brown; Tessa Gargett
Journal:  Front Immunol       Date:  2022-04-06       Impact factor: 8.786

Review 3.  Glucocorticoid-induced tumour necrosis factor receptor-related protein: a key marker of functional regulatory T cells.

Authors:  Simona Ronchetti; Erika Ricci; Maria Grazia Petrillo; Luigi Cari; Graziella Migliorati; Giuseppe Nocentini; Carlo Riccardi
Journal:  J Immunol Res       Date:  2015-04-15       Impact factor: 4.818

Review 4.  Toward a noncytotoxic glioblastoma therapy: blocking MCP-1 with the MTZ Regimen.

Authors:  Michael E Salacz; Richard E Kast; Najmaldin Saki; Ansgar Brüning; Georg Karpel-Massler; Marc-Eric Halatsch
Journal:  Onco Targets Ther       Date:  2016-04-27       Impact factor: 4.147

5.  Mesenchymal Stem Cells Derived and Cultured from Glioblastoma Multiforme Increase Tregs, Downregulate Th17, and Induce the Tolerogenic Phenotype of Monocyte-Derived Cells.

Authors:  Kalina Tumangelova-Yuzeir; Emanuil Naydenov; Ekaterina Ivanova-Todorova; Ekaterina Krasimirova; Georgi Vasilev; Sevdalin Nachev; Dobroslav Kyurkchiev
Journal:  Stem Cells Int       Date:  2019-05-02       Impact factor: 5.443

Review 6.  Tumor progression mechanisms: Insights from the central immune regulation of tissue homeostasis.

Authors:  Natalya Lisovska; Nasrulla Shanazarov
Journal:  Oncol Lett       Date:  2019-04-05       Impact factor: 2.967

7.  Blood-Based Biomarkers for Glioma in the Context of Gliomagenesis: A Systematic Review.

Authors:  Hamza Ali; Romée Harting; Ralph de Vries; Meedie Ali; Thomas Wurdinger; Myron G Best
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

Review 8.  Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites.

Authors:  Powell Perng; Michael Lim
Journal:  Front Oncol       Date:  2015-07-06       Impact factor: 6.244

9.  CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.

Authors:  Richard E Kast; Georg Karpel-Massler; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2014-09-30

10.  Platelet activation parameters and platelet-leucocyte-conjugate formation in glioblastoma multiforme patients.

Authors:  Sascha Marx; Maximilian Splittstöhser; Frederik Kinnen; Eileen Moritz; Christy Joseph; Sebastian Paul; Heiko Paland; Carolin Seifert; Madlen Marx; Andreas Böhm; Edzard Schwedhelm; Kerstin Holzer; Stephan Singer; Christoph A Ritter; Sandra Bien-Möller; Henry W S Schroeder; Bernhard H Rauch
Journal:  Oncotarget       Date:  2018-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.